Literature DB >> 3921665

Blood-brain barrier transport of valproic acid.

E M Cornford, C P Diep, W M Pardridge.   

Abstract

Valproic acid distribution in brain is less than that of other anticonvulsants such as phenytoin or phenobarbital. Possible mechanisms for this decreased distribution space in brain include (a) increased plasma protein binding of valproate relative to the other anticonvulsants and (b) asymmetric blood-brain barrier (BBB) transport of valproate such that the brain-to-blood flux exceeds the blood-to-brain flux. These mechanisms are investigated in the present studies using the intracarotid injection technique in rats and rabbits. In the rat, the brain uptake index (BUI) of [14C]valproate relative to [3H]water is 51 +/- 6%, indicating the blood-to-brain transport of water is twofold greater than that of valproate. However, the BUI of [14C]valproate relative to [3H]water decreased with time after carotid injection during a 4-min washout period, which indicates that brain-to-blood transport of valproate is greater than that of water. This suggests that the permeability of the BBB to valproate is polarized, with antiluminal permeability being much greater than luminal permeability. In rabbits, the BUI of [14C]valproate is 47 +/- 7% in newborns and 17 +/- 6% in adult animals. However, the high drug extraction in newborns may be attributed to decreased cerebral blood flow in the neonate as the BBB permeability-surface area (PS) products are unchanged (e.g., PS = 0.13 and 0.11 ml min-1 X g-1 in the newborn and adult rabbit, respectively). With regard to plasma protein binding effects on valproate transport, brain valproate uptake was also measured in the presence of human, lamb, pig, rat, horse, goat, hamster, dog, and mouse sera. Higher brain uptakes were observed when the unbound fraction of drug increased. However, our data indicate that a fraction of the valproic acid entering the capillaries bound to plasma proteins had the capacity to equilibrate with brain because of enhanced drug dissociation from albumin in the brain microcirculation. Since plasma protein-bound valproate is available for uptake by brain, the major factor underlying the diminished distribution of the drug in brain appears to be the asymmetric transport properties of the BBB to valproic acid.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3921665     DOI: 10.1111/j.1471-4159.1985.tb08793.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  22 in total

Review 1.  The impact of efflux transporters in the brain on the development of drugs for CNS disorders.

Authors:  Eve M Taylor
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Correction of Niemann-Pick type C1 trafficking and activity with the histone deacetylase inhibitor valproic acid.

Authors:  Kanagaraj Subramanian; Darren M Hutt; Samantha M Scott; Vijay Gupta; Shu Mao; William E Balch
Journal:  J Biol Chem       Date:  2020-04-30       Impact factor: 5.157

3.  Histone deacetylase inhibitors de-repress tyrosine hydroxylase expression in the olfactory bulb and rostral migratory stream.

Authors:  Yosuke Akiba; John W Cave; Nami Akiba; Brett Langley; Rajiv R Ratan; Harriet Baker
Journal:  Biochem Biophys Res Commun       Date:  2010-02-17       Impact factor: 3.575

Review 4.  Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems.

Authors:  Akira Tsuji
Journal:  NeuroRx       Date:  2005-01

5.  Study on brain interstitial fluid distribution and blood-brain barrier transport of baclofen in rats by microdialysis.

Authors:  Y Deguchi; K Inabe; K Tomiyasu; K Nozawa; S Yamada; R Kimura
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

Review 6.  Amino Acids in the Development of Prodrugs.

Authors:  Nuno Vale; Abigail Ferreira; Joana Matos; Paula Fresco; Maria João Gouveia
Journal:  Molecules       Date:  2018-09-11       Impact factor: 4.411

7.  Amino Acid Promoieties Alter Valproic Acid Pharmacokinetics and Enable Extended Brain Exposure.

Authors:  Mikko Gynther; Lauri Peura; Monika Vernerová; Jukka Leppänen; Jussi Kärkkäinen; Marko Lehtonen; Jarkko Rautio; Kristiina M Huttunen
Journal:  Neurochem Res       Date:  2016-07-14       Impact factor: 3.996

Review 8.  Human pharmacogenomic variations and their implications for antifungal efficacy.

Authors:  Joseph Meletiadis; Stephen Chanock; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

9.  Plasma binding and transport of diazepam across the blood-brain barrier. No evidence for in vivo enhanced dissociation.

Authors:  R K Dubey; C B McAllister; M Inoue; G R Wilkinson
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

10.  Assessment of valproic acid serum-cerebrospinal fluid transport by microdialysis.

Authors:  P L Golden; K R Brouwer; G M Pollack
Journal:  Pharm Res       Date:  1993-12       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.